194 related articles for article (PubMed ID: 10519917)
21. Effect of dehydroepiandrosterone derivatives on the activity of 5α-reductase isoenzymes and on cancer cell line PC-3.
Bratoeff E; Garrido M; Ramírez-Apan T; Heuze Y; Sánchez A; Soriano J; Cabeza M
Bioorg Med Chem; 2014 Nov; 22(21):6233-41. PubMed ID: 25261928
[TBL] [Abstract][Full Text] [Related]
22. Fungi test for evaluation of new antiandrogenic molecule.
Cabeza M; Quiroz A; Bratoeff E; Heuze I; Ramírez E; Murillo E
Proc West Pharmacol Soc; 2000; 43():29-30. PubMed ID: 11056949
[TBL] [Abstract][Full Text] [Related]
23. New ester derivatives of dehydroepiandrosterone as 5α-reductase inhibitors.
Arellano Y; Bratoeff E; Garrido M; Soriano J; Heuze Y; Cabeza M
Steroids; 2011 Nov; 76(12):1241-6. PubMed ID: 21729714
[TBL] [Abstract][Full Text] [Related]
24. New progesterone derivatives as inhibitors of 5alpha-reductase enzyme and prostate cancer cell growth.
Cabeza M; Bratoeff E; Heuze I; Rojas A; Terán N; Ochoa M; Ramírez-Apan T; Ramírez E; Pérez V; Gracia I
J Enzyme Inhib Med Chem; 2006 Aug; 21(4):371-8. PubMed ID: 17059168
[TBL] [Abstract][Full Text] [Related]
25. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
26. Molecular interactions of progesterone derivatives with 5 alpha-reductase types 1 and 2 and androgen receptors.
Bratoeff E; García P; Heuze Y; Soriano J; Mejía A; Labastida AM; Valencia N; Cabeza M
Steroids; 2010 Jul; 75(7):499-505. PubMed ID: 20359488
[TBL] [Abstract][Full Text] [Related]
27. [Enzyme inhibition in the drug therapy of benign prostatic hyperplasia].
Drsata J
Cas Lek Cesk; 2002 Oct; 141(20):630-5. PubMed ID: 12515038
[TBL] [Abstract][Full Text] [Related]
28. [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
Akakura K; Furuya Y; Ito H
Nihon Rinsho; 1998 Aug; 56(8):2124-8. PubMed ID: 9750520
[TBL] [Abstract][Full Text] [Related]
29. In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors.
Bratoeff E; Cabeza M; Pérez-Ornelas V; Recillas S; Heuze I
J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):275-81. PubMed ID: 18644453
[TBL] [Abstract][Full Text] [Related]
30. Antiandrogens.
Neri RO
Adv Sex Horm Res; 1976; 2():233-62. PubMed ID: 65117
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds.
Nnane IP; Kato K; Liu Y; Long BJ; Lu Q; Wang X; Ling YZ; Brodie A
Endocrinology; 1999 Jun; 140(6):2891-7. PubMed ID: 10342882
[TBL] [Abstract][Full Text] [Related]
32. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptors in benign and malignant prostatic tissue.
Lakey WH; Bruchovsky N; Callaway T; Comeau T; Lieskovsky G; Rennie P; Shnitka T; Wilkin P
Trans Am Assoc Genitourin Surg; 1979; 71():19-22. PubMed ID: 94714
[TBL] [Abstract][Full Text] [Related]
34. Androgen deprivation as a strategy for prostate cancer chemoprevention.
Aquilina JW; Lipsky JJ; Bostwick DG
J Natl Cancer Inst; 1997 May; 89(10):689-96. PubMed ID: 9168183
[No Abstract] [Full Text] [Related]
35. Synthesis and Study of Some 17a-aza-D-homo Steroids as 5α-Reductase Inhibitors.
Rana P; Dhingra N; Arora P; Dhingra R; Monika C; Gupta A
Curr Drug Discov Technol; 2021; 18(5):e22092020186180. PubMed ID: 32962621
[TBL] [Abstract][Full Text] [Related]
36. Anti-androgens for the treatment of hirsutism.
Carmina E
Expert Opin Investig Drugs; 2002 Mar; 11(3):357-63. PubMed ID: 11866665
[TBL] [Abstract][Full Text] [Related]
37. [Non-surgical treatment of benign prostatic hypertrophy. Current status of the problem].
Van Cangh PJ
Bull Mem Acad R Med Belg; 1992; 147(1-2):125-35; discussion 135-7. PubMed ID: 1384903
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological activity of progesterone derivatives as 5alpha-reductase inhibitors, and their effect on hamster prostate weight.
Bratoeff E; Zambrano A; Heuze I; Palacios A; Ramírez D; Cabeza M
J Enzyme Inhib Med Chem; 2010 Jun; 25(3):306-11. PubMed ID: 19874206
[TBL] [Abstract][Full Text] [Related]
39. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
[TBL] [Abstract][Full Text] [Related]
40. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II.
Pais P
Adv Ther; 2010 Aug; 27(8):555-63. PubMed ID: 20623347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
